close

Main navigation

close
Erythropoietin (EPO) Drugs Market

Erythropoietin Drugs Market Forecast, Trend Analysis & Competition Tracking - Global Industry Insights 2015 to 2031

  • 2702

  • Upcoming

  • NA

  • PDF

    • ☆ ★
    • ☆ ★
    • ☆ ★
    • ☆ ★
    • ☆ ★

Select License

  • It allows one person, the buyer, to have sole right and access to the purchased report. Further distribution of product is strictly prohibited.
  • It allows the purchased product to be shared among 5 people within your organization at maximum.
  • It allows the purchased product to be shared among all employees of your organization irrespective of their geographical location.
Request sample

  • Erythropoietin (EPO) is a hormone produced by the kidneys and small amounts secreted by the liver. Erythropoietin is an essential protein hormone that produces red blood cells. The red blood cells transport oxygen to all tissues in the human body. The hormone is synthesized in the kidneys, and its secretion depends on the amount of oxygen delivered to the organ. The interstitial fibroblasts produce Erythropoietin in the kidney, closely related to the capillaries around the renal tubules and the proximal tortuous tubules.

    Request Covid - 19 Impact

    Demand for Erythropoietin Drugs from 2015 to 2020 Vs Future Market Projections for 2021-2031

    From 2015 to 2020, sales of erythropoietin drugs were significantly high, expanding at under 7.1% CAGR. This is due to the increased usage rate in anemia and patients with cancer and chronic renal failure.

    The onset of the COVID-19 pandemic has drastically affected various manufacturing and supply chain operations for multiple industries, the healthcare sector included. Most erythropoietin drugs manufacturers have stated that the supply of medicines, which had been temporarily interrupted, has subsequently led to the slowdown/suspension of respective operations, in turn, negatively impacting this industry.

    Global Erythropoietin Drugs Market Revenue Outlook:

    The Global Erythropoietin Drugs market was valued at US$ 7.6 Bn in 2020 and is projected to register а САGR of 7.3% by 2031.

    Nonetheless, various industry players in the global Erythropoietin Drugs market are now increasing their focus towards the establishment of successful collaborations, acquisitions, and joint venture activities as a means to enhance their respective customer bases. These players are also increasing their supply capabilities to meet customer requirements on a local and global scale. This factor, paired with promising industrialization prospects in developing economies of the Asia-Pacific region, such as China, India, Taiwan, Indonesia, etc., are expected to create massive business opportunities for key players over the forecast period.

    To learn more about this report, request for sample report

    What Is The Effect Of The Erythropoietin Drugs Market For The Treatment Of Cancer and Anemia?

    The increasing prevalence of cancer, ESRD (End-Stage Renal Disease), and HIV have primarily contributed to the surge in demand for EPO drugs. Approximately 20% of cancer/HIV patients and about 70% of ESRD patients receive chemotherapy, which usually results in anemia among such patients, thereby requiring appropriate EPO treatments. This is the significant revenue-generating factor for the erythropoietin market.

    Anemia is observed in most patients undergoing cancer treatments. The severity of a patient's disease depends on the type of chemotherapy needed, the type and stage of tumor formations, and the physiological characteristics of the patient. Severe anemia, especially in children and the elderly, can cause fatigue, weakness, and depression, which severely reduces the quality of life of cancer patients. Erythropoietin drugs have been proven to be the best form of treatment for anemia. This, in turn, is expected to boost the growth of the erythropoietin market over the forecast period.

    Stringent Rules And Regulations Impact The Growth Of The Global Erythropoietin Drugs Market

    The European government has imposed strict rules and regulations concerning the production and sale of Erythropoietin. Companies manufacturing Erythropoietin must comply with Marketing Authorization (MA) norms under provisions of Regulation (EC) No. 726/04 issued by the EC. The regulatory policy for biosimilars is complex in Europe and is mainly governed by the European Medicines Agency (EMEA). This has been a major restraint hindering the revenue growth of the erythropoietin market.

    Opportunities For The Manufacturer Of The Erythropoietin Drugs

    The expiration of patents for major biological agents will create opportunities for erythropoietin biosimilars to enter the market over the next few years. For example, Amgen's Epogen patent expired in 2018, which provided a huge opportunity for other companies to enter the erythropoietin industry. Hence, it is expected that there will be an increase in the number of new entrants investing in this sector, resulting in subsequent revenue growth.

    • Amgen Inc. has developed Darbepoetin-alfa as a new erythropoietin drug marketed under the Aranesp brand name. This medicinal product is patented in the United States and expires in 2024.

    COVID–19 Impact On Healthcare Sector

    The COVID-19 pandemic caused by the SARS-CoV-2 virus led to a near-worldwide lockdown. This has had a disastrous impact on export-import activities of drugs used for various treatments. It also completely changed the future approach towards medicine and medical devices. The pharmaceutical industry was affected by a similar challenge. Pharmaceutical companies are responding to the rapid challenges arising from disruption in supply chains and the need to change business processes and a shift towards telecommunication and telemedicine. COVID-19 may be seen as the century's opportunity for the pharmaceutical industry, increasing the demand for prescription medicines, vaccines, and medical devices. Demand change, supply shortages, panic buying and stocking, regulatory changes, and shift of communication and promotions to remote interactions through technology and research and development (R&D) process changes can be seen as short-term impacts of COVID-19 on the health market. The COVID-19 pandemic made healthcare professionals – take extra measures to deliver exceptional care in the safest possible environment. Protocols were reassessed, adapted, and rewritten to fulfill the requirements to stop the spread of the coronavirus. Various pharmaceutical companies with local government support and initiatives are reducing the burdens on societies and economies globally. At the same time, governments are now getting ready to ensure the large-scale distribution of various medicines used for the treatment of numerous chronic diseases.

    Detailed Recent Clinical Trial For Erythropoietin

    • Neonatal Erythropoietin and Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)
      • Hypoxic-ischemic encephalopathy (HIE), a condition of reduced blood and oxygen flow to a baby's brain near the time of birth, may cause death or neurologic disability. Cooling therapy (hypothermia) provides some protection, but about half of affected infants still have a poor outcome. This clinical trial will determine if the drug erythropoietin, given with hypothermia, is safe to use as a treatment that may further reduce the risk of neurologic deficits after HIE.
    • Erythropoietin as a candidate for supportive treatment of severe COVID-19
    • In light of the present therapeutic situation in COVID-19, any measure to improve the course and outcome of seriously affected individuals is of utmost importance. It supports the use of human recombinant Erythropoietin (EPO) for ameliorating course and outcome of seriously ill COVID-19 patients. Each introduced by a summary of respective COVID-19 references, how EPO may target a number of the gravest sequelae of these patients. EPO is expected to: (1) improve respiration at several levels including lung, brainstem, spinal cord, and respiratory muscles; (2) counteract overshooting inflammation caused by cytokine storm/ inflammasome; (3) act neuroprotective and neurodegenerative in the brain and peripheral nervous system

    Country-Wise Analysis

    How Is The Growing Popularity Of Erythropoietin Drugs Sales In Germany?

    The market for Erythropoietin Drugs in Germany is likely to expand at under 9.1% CAGR until 2031. This is because suppliers in the European erythropoietin drug market are expected to improve their given distribution channels. This move may encourage suppliers to find more distributors in their respective supply-chain systems. This factor is further expected to increase competition among market participants, promoting opportunities for additional revenue growth in this industry.

    Competitive Landscape

    The Erythropoietin Drugs landscape appears highly consolidated, with a major chunk of it being dominated by US players.

    • Johnson & Johnson
    • Roche Holding AG
    • Pfizer Inc. (Hospira)
    • Amgen, Inc.
    • Kirin Holdings Co., Ltd. (Kyowa Hakko Kirin)
    • Teva Pharmaceutical Industries Ltd
    • LG Corp. (LG Life Sciences Ltd.)
    • Intas Pharmaceuticals Ltd.
    • Biocon Ltd.
    • Emcure Pharmaceuticals
    • Other Players

    Report Scope

    • Forecast Period: 2022-2031
    • Actual Year: 2021
    • Historical Data Available for: 2015-2020

    Key Regions Covered

    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa

    Key Segments Covered

    Erythropoietin Drugs Market, By Product Type

    • Epoetin-Alfa
    • Epoetin-Beta
    • Darbepoetin-Alfa
    • Other Product Types

    Erythropoietin Drugs Market, By Drug Class

    • Biologics
    • Biosimilars

    Erythropoietin Drugs Market, By Indications

    • Cancer
    • Hematology
    • Renal Diseases
    • Neurology
    Particular Scope
    Region

    • North America
      • US
      • Canada
    • Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    Historical Period 2015-2020
    Base Year 2021
    Forecast Period 2022–2031
    Revenue in US$ Mn

    To learn more about this report, request for sample report

    • Johnson & Johnson
    • Roche Holding AG
    • Pfizer Inc. (Hospira)
    • Amgen, Inc.
    • Kirin Holdings Co., Ltd. (Kyowa Hakko Kirin)
    • Teva Pharmaceutical Industries Ltd
    • LG Corp. (LG Life Sciences Ltd.)
    • Intas Pharmaceuticals Ltd.
    • Biocon Ltd.
    • Emcure Pharmaceuticals
    • Other Players
    • Chapter 1 Global Erythropoietin Drugs MarketOutlook
      • 1.1 Introduction
      • 1.2 Segmentation of Erythropoietin Drugs Market Based On Product Type, Drug Class, Indications and Region
      • 1.3 Market Drivers
      • 1.4 Market Restraints
      • 1.5 Market Opportunities
      • 1.6 Market Trends
      • 1.7 Macro-economic Factors
      • 1.8 Regulatory Framework
      • 1.9 Global Erythropoietin Drugs Market Pricing Analysis by Region, 2021
      • 1.10 Opportunity Map Analysis
        • 1.10.1 Optimistic Scenario
        • 1.10.2 Likely Scenario
        • 1.10.3 Conservative Scenario
      • 1.11 Opportunity Orbits
      • 1.12 Market Investment Feasibility Index
      • 1.13 PEST Analysis
      • 1.14 PORTER’S Five Force Analysis
      • 1.15 Drivers & Restraints Impact Analysis
      • 1.16 Marketing Strategy
      • 1.17 Product Life Cycle Analysis
      • 1.18 Value Chain Analysis
      • 1.19 Cost Structure Analysis
      • 1.20 Regional Market Share and BPS Analysis in {d.keyword}
      • 1.21 COVID-19 Impact Analysis
    • Chapter 2 Global Erythropoietin Drugs MarketOverview
      • 2.1 Global Market Value & Volume Comparison by Product Type (2015-2031)
        • 2.1.1 Global Market Value & Volume Market Share by Product Type in 2021
        • 2.1.2 Global Market Attractiveness Analysis by Product Type, 2015–2022
      • 2.2 Global Market Value & Volume Comparison by Drug Class (2015-2031)
        • 2.2.1 Global Market Value & Volume Market Share by Drug Class in 2021
        • 2.2.2 Global Market Attractiveness Analysis by Drug Class, 2015–2022
      • 2.3 Global Market by Indications
        • 2.3.1 Global Market Value & Volume Comparison by Indications (2015-2031)
        • 2.3.2 Global Market Value & Volume Market Share by Indications in 2021
        • 2.3.3 Global Market Attractiveness Analysis by Indications, 2015–2022
      • 2.4 Global Market Outlook by Region
        • 2.4.1 Global Market Value & Volume Comparison by Region (2015-2031)
        • 2.4.2 Global Market Value & Volume Market Share by Region in 2021
        • 2.4.3 Global Market Attractiveness Analysis by Region, 2015–2022
      • 2.5 Global Market Outlook (2015-2031)
        • 2.5.1 Global Market Value & Volume (2015–2022)
        • 2.5.2 Global Market Value & Volume (2023-2031)
      • 2.6 Global Market Value & Volume by Regions
        • 2.6.1 Global Market Value & Volume Comparison by Region (2015–2022)
        • 2.6.2 Global Market Value & Volume Comparison by Region (2023-2031)
      • 2.7 Global Market Value & Volume by Product Type
        • 2.7.1 Global Market Value & Volume Comparison by Product Type (2015–2022)
        • 2.7.2 Global Market Value & Volume Comparison by Product Type (2023-2031)
      • 2.8 Global Market Value & Volume by Drug Class
        • 2.8.1 Global Market Value & Volume Comparison by Drug Class (2015–2022)
        • 2.8.2 Global Market Value & Volume Comparison by Drug Class (2023-2031)
      • 2.9 Global Market Value & Volume by Indications
        • 2.9.1 Global Market Value & Volume Comparison by Indications (2015–2022)
        • 2.9.2 Global Market Value & Volume Comparison by Indications (2023-2031)
      • 2.10 Global Market Y-o-Y Growth Rate Comparison 2016–2031
        • 2.10.1 Global Market Y-o-Y Growth Rate by Region
        • 2.10.2 Global Market Y-o-Y Growth Rate by Product Type
        • 2.10.3 Global Market Y-o-Y Growth Rate by Drug Class
        • 2.10.4 Global Market Y-o-Y Growth Rate by Indications
      • 2.11 Global Market Share Comparison 2015–2030
        • 2.11.1 Global Market Share by Region
        • 2.11.2 Global Market Share by Product Type
        • 2.11.3 Global Market Share by Drug Class
        • 2.11.4 Global Market Share by Indications
    • Chapter 3 North America Erythropoietin Drugs MarketOverview
      • 3.1 North America Market by Product Type
        • 3.1.1 North America Market Value & Volume Comparison by Product Type (2015-2031)
        • 3.1.2 North America Market Value & Volume Market Share by Product Type in 2021
      • 3.2 North America Market Value & Volume Comparison by Drug Class (2015-2031)
        • 3.2.1 North America Market Value & Volume Market Share by Drug Class in 2021
        • 3.2.2 North America Market Attractiveness Analysis by Drug Class, 2015–2022
      • 3.3 North America Market by Indications
        • 3.3.1 North America Market Value & Volume Comparison by Indications (2015-2031)
        • 3.3.2 North America Market Value & Volume Market Share by Indications in 2021
        • 3.3.3 North America Market Attractiveness Analysis by Indications, 2015–2022
      • 3.4 North America Market Outlook by Region
        • 3.4.1 North America Market Value & Volume Comparison by Region (2015-2031)
        • 3.4.2 North America Market Value & Volume Market Share by Region in 2021
        • 3.4.3 North America Market Attractiveness Analysis by Region, 2015–2022
      • 3.5 North America Market Outlook (2015-2031)
        • 3.5.1 North America Market Value & Volume (2015–2022)
        • 3.5.2 North America Market Value & Volume (2023-2031)
      • 3.6 North America Market Value & Volume by Regions
        • 3.6.1 North America Market Value & Volume Comparison by Region (2015–2022)
        • 3.6.2 North America Market Value & Volume Comparison by Region (2023-2031)
      • 3.7 North America Market Value & Volume by Product Type
        • 3.7.1 North America Market Value & Volume Comparison by Product Type (2015–2022)
        • 3.7.2 North America Market Value & Volume Comparison by Product Type (2023-2031)
      • 3.8 North America Market Value & Volume by Drug Class
        • 3.8.1 North America Market Value & Volume Comparison by Drug Class (2015–2022)
        • 3.8.2 North America Market Value & Volume Comparison by Drug Class (2023-2031)
      • 3.9 North America Market Value & Volume by Indications
        • 3.9.1 North America Market Value & Volume Comparison by Indications (2015–2022)
        • 3.9.2 North America Market Value & Volume Comparison by Indications (2023-2031)
      • 3.10 North America Market Y-o-Y Growth Rate Comparison 2016–2031
        • 3.10.1 North America Market Y-o-Y Growth Rate by Region
        • 3.10.2 North America Market Y-o-Y Growth Rate by Product Type
        • 3.10.3 North America Market Y-o-Y Growth Rate by Drug Class
        • 3.10.4 North America Market Y-o-Y Growth Rate by Indications
      • 3.11 North America Market Share Comparison 2015–2030
        • 2.11.1 North America Market Share by Region
        • 3.11.2 North America Market Share by Product Type
        • 3.11.3 North America Market Share by Drug Class
        • 3.11.4 North America Market Share by Indications
    • Chapter 4 Europe Erythropoietin Drugs MarketOverview
      • 4.1 Europe Market by Product Type
        • 4.1.1 Europe Market Value & Volume Comparison by Product Type (2015-2031)
        • 4.1.2 Europe Market Value & Volume Market Share by Product Type in 2021
      • 4.2 Europe Market Value & Volume Comparison by Drug Class (2015-2031)
        • 4.2.1 Europe Market Value & Volume Market Share by Drug Class in 2021
        • 4.2.2 Europe Market Attractiveness Analysis by Drug Class, 2015–2022
      • 4.3 Europe Market by Indications
        • 4.3.1 Europe Market Value & Volume Comparison by Indications (2015-2031)
        • 4.3.2 Europe Market Value & Volume Market Share by Indications in 2021
        • 4.3.3 Europe Market Attractiveness Analysis by Indications, 2015–2022
      • 4.4 Europe Market Outlook by Region
        • 4.4.1 Europe Market Value & Volume Comparison by Region (2015-2031)
        • 4.4.2 Europe Market Value & Volume Market Share by Region in 2021
        • 4.4.3 Europe Market Attractiveness Analysis by Region, 2015–2022
      • 4.5 Europe Market Outlook (2015-2031)
        • 4.5.1 Europe Market Value & Volume (2015–2022)
        • 4.5.2 Europe Market Value & Volume (2023-2031)
      • 4.6 Europe Market Value & Volume by Regions
        • 4.6.1 Europe Market Value & Volume Comparison by Region (2015–2022)
        • 4.6.2 Europe Market Value & Volume Comparison by Region (2023-2031)
      • 4.7 Europe Market Value & Volume by Product Type
        • 4.7.1 Europe Market Value & Volume Comparison by Product Type (2015–2022)
        • 4.7.2 Europe Market Value & Volume Comparison by Product Type (2023-2031)
      • 4.8 Europe Market Value & Volume by Drug Class
        • 4.8.1 Europe Market Value & Volume Comparison by Drug Class (2015–2022)
        • 4.8.2 Europe Market Value & Volume Comparison by Drug Class (2023-2031)
      • 4.9 Europe Market Value & Volume by Indications
        • 4.9.1 Europe Market Value & Volume Comparison by Indications (2015–2022)
        • 4.9.2 Europe Market Value & Volume Comparison by Indications (2023-2031)
      • 4.9 Europe Market Y-o-Y Growth Rate Comparison 2016–2031
        • 4.10.1 Europe Market Y-o-Y Growth Rate by Region
        • 4.10.2 Europe Market Y-o-Y Growth Rate by Product Type
        • 4.10.3 Europe Market Y-o-Y Growth Rate by Drug Class
        • 4.10.4 Europe Market Y-o-Y Growth Rate by Indications
      • 4.11 Europe Market Share Comparison 2015–2030
        • 4.11.1 Europe Market Share by Region
        • 4.11.2 Europe Market Share by Product Type
        • 4.11.3 Europe Market Share by Drug Class
        • 4.11.4 Europe Market Share by Indications
    • Chapter 5 Asia-Pacific Erythropoietin Drugs MarketOverview
      • 5.1 Asia-Pacific Market by Product Type
        • 5.1.1 Asia-Pacific Market Value & Volume Comparison by Product Type (2015-2031)
        • 5.1.2 Asia-Pacific Market Value & Volume Market Share by Product Type in 2021
      • 5.2 Asia-Pacific Market Value & Volume Comparison by Drug Class (2015-2031)
        • 5.2.1 Asia-Pacific Market Value & Volume Market Share by Drug Class in 2021
        • 5.2.2 Asia-Pacific Market Attractiveness Analysis by Drug Class, 2015–2022
      • 5.3 Asia-Pacific Market by Indications
        • 5.3.1 Asia-Pacific Market Value & Volume Comparison by Indications (2015-2031)
        • 5.3.2 Asia-Pacific Market Value & Volume Market Share by Indications in 2021
        • 5.3.3 Asia-Pacific Market Attractiveness Analysis by Indications, 2015–2022
      • 5.4 Asia-Pacific Market Outlook by Region
        • 5.4.1 Asia-Pacific Market Value & Volume Comparison by Region (2015-2031)
        • 5.4.2 Asia-Pacific Market Value & Volume Market Share by Region in 2021
        • 5.4.3 Asia-Pacific Market Attractiveness Analysis by Region, 2015–2022
      • 5.5 Asia-Pacific Market Outlook (2015-2031)
        • 5.5.1 Asia-Pacific Market Value & Volume (2015–2022)
        • 5.5.2 Asia-Pacific Market Value & Volume (2023-2031)
      • 5.6 Asia-Pacific Market Value & Volume by Regions
        • 5.6.1 Asia-Pacific Market Value & Volume Comparison by Region (2015–2022)
        • 5.6.2 Asia-Pacific Market Value & Volume Comparison by Region (2023-2031)
      • 5.7 Asia-Pacific Market Value & Volume by Product Type
        • 5.7.1 Asia-Pacific Market Value & Volume Comparison by Product Type (2015–2022)
        • 5.7.2 Asia-Pacific Market Value & Volume Comparison by Product Type (2023-2031)
      • 5.8 Asia-Pacific Market Value & Volume by Drug Class
        • 5.8.1 Asia-Pacific Market Value & Volume Comparison by Drug Class (2015–2022)
        • 5.8.2 Asia-Pacific Market Value & Volume Comparison by Drug Class (2023-2031)
      • 5.9 Asia-Pacific Market Value & Volume by Indications
        • 5.9.1 Asia-Pacific Market Value & Volume Comparison by Indications (2015–2022)
        • 5.9.2 Asia-Pacific Market Value & Volume Comparison by Indications (2023-2031)
      • 5.10 Asia-Pacific Market Y-o-Y Growth Rate Comparison 2016–2031
        • 5.10.1 Asia-Pacific Market Y-o-Y Growth Rate by Region
        • 5.10.2 Asia-Pacific Market Y-o-Y Growth Rate by Product Type
        • 5.10.3 Asia-Pacific Market Y-o-Y Growth Rate by Drug Class
        • 5.10.4 Asia-Pacific Market Y-o-Y Growth Rate by Indications
      • 5.11 Asia-Pacific Market Share Comparison 2015–2030
        • 5.11.1 Asia-Pacific Market Share by Region
        • 5.11.2 Asia-Pacific Market Share by Product Type
        • 5.11.3 Asia-Pacific Market Share by Drug Class
        • 5.11.4 Asia-Pacific Market Share by Indications
    • Chapter 6 Latin America Erythropoietin Drugs MarketOverview
      • 6.1 Latin America Market by Product Type
        • 6.1.1 Latin America Market Value & Volume Comparison by Product Type (2015-2031)
        • 6.1.2 Latin America Market Value & Volume Market Share by Product Type in 2021
      • 6.2 Latin America Market Value & Volume Comparison by Drug Class (2015-2031)
        • 6.2.1 Latin America Market Value & Volume Market Share by Drug Class in 2021
        • 6.2.2 Latin America Market Attractiveness Analysis by Drug Class, 2015–2022
      • 6.3 Latin America Market by Indications
        • 6.3.1 Latin America Market Value & Volume Comparison by Indications (2015-2031)
        • 6.3.2 Latin America Market Value & Volume Market Share by Indications in 2021
        • 6.3.3 Latin America Market Attractiveness Analysis by Indications, 2015–2022
      • 6.4 Latin America Market Outlook by Region
        • 6.4.1 Latin America Market Value & Volume Comparison by Region (2015-2031)
        • 6.4.2 Latin America Market Value & Volume Market Share by Region in 2021
        • 6.4.3 Latin America Market Attractiveness Analysis by Region, 2015–2022
      • 6.5 Latin America Market Outlook (2015-2031)
        • 6.5.1 Latin America Market Value & Volume (2015–2022)
        • 6.5.2 Latin America Market Value & Volume (2023-2031)
      • 6.6 Latin America Market Value & Volume by Regions
        • 6.6.1 Latin America Market Value & Volume Comparison by Region (2015–2022)
        • 6.6.2 Latin America Market Value & Volume Comparison by Region (2023-2031)
      • 6.7 Latin America Market Value & Volume by Product Type
        • 6.7.1 Latin America Market Value & Volume Comparison by Product Type (2015–2022)
        • 6.7.2 Latin America Market Value & Volume Comparison by Product Type (2023-2031)
      • 6.8 Latin America Market Value & Volume by Drug Class
        • 6.8.1 Latin America Market Value & Volume Comparison by Drug Class (2015–2022)
        • 6.8.2 Latin America Market Value & Volume Comparison by Drug Class (2023-2031)
      • 6.9 Latin America Market Value & Volume by Indications
        • 6.9.1 Latin America Market Value & Volume Comparison by Indications (2015–2022)
        • 6.9.2 Latin America Market Value & Volume Comparison by Indications (2023-2031)
      • 6.10 Latin America Market Y-o-Y Growth Rate Comparison 2016–2031
        • 6.10.1 Latin America Market Y-o-Y Growth Rate by Region
        • 6.10.2 Latin America Market Y-o-Y Growth Rate by Product Type
        • 6.10.3 Latin America Market Y-o-Y Growth Rate by Drug Class
        • 6.10.4 Latin America Market Y-o-Y Growth Rate by Indications
      • 6.11 Latin America Market Share Comparison 2015–2030
        • 6.11.1 Latin America Market Share by Region
        • 6.11.2 Latin America Market Share by Product Type
        • 6.11.3 Latin America Market Share by Drug Class
        • 6.11.4 Latin America Market Share by Indications
    • Chapter 7 MEA Erythropoietin Drugs MarketOverview
      • 7.1 MEA Market by Product Type
        • 7.1.1 MEA Market Value & Volume Comparison by Product Type (2015-2031)
        • 7.1.2 MEA Market Value & Volume Market Share by Product Type in 2021
      • 7.2 MEA Market Value & Volume Comparison by Drug Class (2015-2031)
        • 7.2.1 MEA Market Value & Volume Market Share by Drug Class in 2021
        • 7.2.2 MEA Market Attractiveness Analysis by Drug Class, 2015–2022
      • 7.3 MEA Market by Indications
        • 7.3.1 MEA Market Value & Volume Comparison by Indications (2015-2031)
        • 7.3.2 MEA Market Value & Volume Market Share by Indications in 2021
        • 7.3.3 MEA Market Attractiveness Analysis by Indications, 2015–2022
      • 7.4 MEA Market Outlook by Region
        • 7.4.1 MEA Market Value & Volume Comparison by Region (2015-2031)
        • 7.4.2 MEA Market Value & Volume Market Share by Region in 2021
        • 7.4.3 MEA Market Attractiveness Analysis by Region, 2015–2022
      • 7.5 MEA Market Outlook (2015-2031)
        • 7.5.1 MEA Market Value & Volume (2015–2022)
        • 7.5.2 MEA Market Value & Volume (2023-2031)
      • 7.5 MEA Market Value & Volume by Regions
        • 7.6.1 MEA Market Value & Volume Comparison by Region (2015–2022)
        • 7.6.2 MEA Market Value & Volume Comparison by Region (2023-2031)
      • 7.7 MEA Market Value & Volume by Product Type
        • 7.7.1 MEA Market Value & Volume Comparison by Product Type (2015–2022)
        • 7.7.2 MEA Market Value & Volume Comparison by Product Type (2023-2031)
      • 7.8 MEA Market Value & Volume by Drug Class
        • 7.8.1 MEA Market Value & Volume Comparison by Drug Class (2015–2022)
        • 7.8.2 MEA Market Value & Volume Comparison by Drug Class (2023-2031)
      • 7.9 MEA Market Value & Volume by Indications
        • 7.9.1 MEA Market Value & Volume Comparison by Indications (2015–2022)
        • 7.9.2 MEA Market Value & Volume Comparison by Indications (2023-2031)
      • 7.10 MEA Market Y-o-Y Growth Rate Comparison 2016–2031
        • 7.10.1 MEA Market Y-o-Y Growth Rate by Region
        • 7.10.2 MEA Market Y-o-Y Growth Rate by Product Type
        • 7.10.3 MEA Market Y-o-Y Growth Rate by Drug Class
        • 7.10.4 MEA Market Y-o-Y Growth Rate by Indications
      • 7.11 MEA Market Share Comparison 2015–2030
        • 7.11.1 MEA Market Share by Region
        • 7.11.2 MEA Market Share by Product Type
        • 7.11.3 MEA Market Share by Drug Class
        • 7.11.4 MEA Market Share by Indications
    • Chapter 8 Global Erythropoietin Drugs Market Company Profiles
      • 8.1 Market Competition Scenario Analysis, By Company
      • 8.2 Competitor Landscape
      • 8.3 Company Share Analysis
      • 8.4 Company Profiles
        • 8.4.1 Johnson & Johnson
          • 8.4.1.1 Company Overview
          • 8.4.1.2 Business Description
          • 8.4.1.3 Product Portfolio
          • 8.4.1.4 Key Financials
          • 8.4.1.5 Key Developments
          • 8.4.1.6 SWOT Analysis
        • 8.4.2 Roche Holding AG
          • 8.4.2.1 Company Overview
          • 8.4.2.2 Business Description
          • 8.4.2.3 Product Portfolio
          • 8.4.2.4 Key Financials
          • 8.4.2.5 Key Developments
          • 8.4.2.6 SWOT Analysis
        • 8.4.3 Pfizer Inc. (Hospira)
          • 8.4.3.1 Company Overview
          • 8.4.3.2 Business Description
          • 8.4.3.3 Product Portfolio
          • 8.4.3.4 Key Financials
          • 8.4.3.5 Key Developments
          • 8.4.3.6 SWOT Analysis
        • 8.4.4 Emcure Pharmaceuticals
          • 8.4.4.1 Company Overview
          • 8.4.4.2 Business Description
          • 8.4.4.3 Product Portfolio
          • 8.4.4.4 Key Financials
          • 8.4.4.5 Key Developments
          • 8.4.4.6 SWOT Analysis
        • 8.4.5 Amgen, Inc.
          • 8.4.5.1 Company Overview
          • 8.4.5.2 Business Description
          • 8.4.5.3 Product Portfolio
          • 8.4.5.4 Key Financials
          • 8.4.5.5 Key Developments
          • 8.4.5.6 SWOT Analysis
        • 8.4.6 Kirin Holdings Co., Ltd. (Kyowa Hakko Kirin)
          • 8.4.6.1 Company Overview
          • 8.4.6.2 Business Description
          • 8.4.6.3 Product Portfolio
          • 8.4.6.4 Key Financials
          • 8.4.6.5 Key Developments
          • 8.4.6.6 SWOT Analysis
        • 8.4.7 Teva Pharmaceutical Industries Ltd
          • 8.4.7.1 Company Overview
          • 8.4.7.2 Business Description
          • 8.4.7.3 Product Portfolio
          • 8.4.7.4 Key Financials
          • 8.4.7.5 Key Developments
          • 8.4.7.6 SWOT Analysis
        • 8.4.8 LG Corp. (LG Life Sciences Ltd.)
          • 8.4.8.1 Company Overview
          • 8.4.8.2 Business Description
          • 8.4.8.3 Product Portfolio
          • 8.4.8.4 Key Financials
          • 8.4.8.5 Key Developments
          • 8.4.8.6 SWOT Analysis
        • 8.4.9 Intas Pharmaceuticals Ltd.
          • 8.4.9.1 Company Overview
          • 8.4.9.2 Business Description
          • 8.4.9.3 Product Portfolio
          • 8.4.9.4 Key Financials
          • 8.4.9.5 Key Developments
          • 8.4.9.6 SWOT Analysis
        • 8.4.10 Biocon Ltd.
          • 8.4.10.1 Company Overview
          • 8.4.10.2 Business Description
          • 8.4.10.3 Product Portfolio
          • 8.4.10.4 Key Financials
          • 8.4.10.5 Key Developments
          • 8.4.10.6 SWOT Analysis
        • 8.4.11 Other Key Players
    • Chapter 9 Research Methodology
      • 9.1 Research Methodology
      • 9.2 Primary Research
      • 9.3 Secondary Research
      • 9.4 Report Scope
    • Chapter 10 About Us
      • 10.1 Who we are:
    • Chapter 11 Disclaimer

    To learn more about this report, request for sample report

  • Inquiry Form

    • I wish to see a sample of this report because.




    • Request for Customization
      message

    Why Choose Us

    • 360 Degree Approach
    • Growth Consulting
    • 24/7 Research Support
    • Comprehensive-Level of Customization
    • Comprehensive-Level of Customization
    • Competitive Intelligence
    • Single-Country/ Region Intelligence
    • Post-Sale Service Assistance
    • Access to Lead Analysts
    • Available in PDF, Excel, Word/ PPT

  • Request for Customization

    • I wish to see a sample of this report because.




    • Request for Customization
      message

RELATED REPORTS

OUR CLIENTS

Don't just take our word. We are trusted by these great companies!

MARKET RESEARCH REPORTS

MarketResearch.Biz (Powered by Prudour Pvt. Ltd.) delivers customized research solutions by actuating its broad spectrum of research methodologies, databases, and resources, and this is further strengthened by our global experience in syndicated and customized industry projects.

Our tailor-made research services include quick market scans, country reports, in-depth market analysis, competition monitoring, consumer research and satisfaction studies, supplier research, growth planning, and quite a lot more.

SHORT NAVIGATION

CONTACT US

Copyright © 2021 Prudour Private Limited. All Rights Reserved.

Powered by Pvt. Ltd.

Speak to Analyst
×

Request a call

person
phone
email
message

Customer Care

+1 (347) 796-4335